- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|Approved drug?||Yes (FDA (2016), EMA (2017))|
|International Nonproprietary Names|
|MPDL3280A | Tecentriq®|
|Atezolizumab (MPDL3280A) is a monoclonal antibody directed against programmed death-1 ligand-1 (PD-L1, aka CD274), an important immunopharmacological drug discovery target in immuno-oncology.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequence analysis using the light chain variable region of atezolizumab provides a 100% match to sequence 21 from patent US8217149. An X-ray crystal structure of the PD-L1/atezolizumab complex has been submitted to the RCSB PDB (accession 5X8L) .
|GtoPdb PubChem SID||249565671|
|Search PubMed clinical trials||atezolizumab|
|Search PubMed titles||atezolizumab|
|Search PubMed titles/abstracts||atezolizumab|